Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 3/20 | 0.50 |
| ▸ | TGM2 | P21980 | 3/20 | 0.50 |
| ▸ | TGM1 | P22735 | 3/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30490344 | 0.92 | F13A1 (0.48) | F13A1TGM2TGM1CACNA1BGPR119 | |
| SCHEMBL25253376 | 0.86 | CACNA1B (0.48) | CACNA1BALDH1A1SPR | |
| SCHEMBL25258995 | 0.80 | RORC (0.47) | RORCALDH1A1GPR183 | |
| SCHEMBL25371482 | 0.79 | EPHX2 (0.60) | F13A1TGM2TGM1 | |
| SCHEMBL26064728 | 0.79 | NAMPT (0.43) | F13A1TGM2TGM1GPR119RORC | |
| SCHEMBL23850261 | 0.78 | TRPV4 (0.44) | CACNA1BALDH1A1 | |
| SCHEMBL30409323 | 0.78 | MGLL (0.43) | CACNA1BALDH1A1 | |
| SCHEMBL25146124 | 0.78 | MGLL (0.43) | CACNA1BALDH1A1 | |
| SCHEMBL23850257 | 0.78 | TGM2 (0.50) | F13A1TGM2TGM1GPR119MAPT | |
| SCHEMBL25145672 | 0.77 | MEN1 (0.46) | CACNA1BMAPTALDH1A1SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | CBR3, BRIX1, CCNY | F13A1 525/4885TGM2 4571/4885TGM1 3547/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | F13A1 525/4885TGM2 4571/4885TGM1 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.